ALPHA COGNITION INC. NEW

Alpha Cognition reported markedly better Q2/2026 results: ZUNVEYL revenue rose to about $6.0 million (sequential +71%, vs. $1.7 million a year earlier). Net loss narrowed to $8.8 million ($0.40/share) from $13.2 million ($0.82) year‑on‑year, and gross margin was around 94%. Management lowered the annual cost forecast to $50–54 million and reiterated the goal of becoming operationally profitable in 2027; dispensed packs and the physician base grew significantly, prompting a strong premarket jump in the stock. » Plus sur de.investing.com

Alpha Cognition reports Q2 net product revenues of $6.0 million for the Alzheimer’s drug ZUNVEYL, up about 71% from the prior quarter; bottles dispensed rose to 8,294 and monthly demand in June reached 2,997. The number of prescribing physicians increased to 1,347, repeat prescribers to 1,024, and market penetration in long-term care facilities was expanded. Net loss fell to $8.8 million ($0.40 per share) versus $13.2 million a year earlier; cash as of June 30: $41.4 million. Alpha Cognition lowers its full-year R&D and SG&A guidance to $50–54 million, launches the phase‑4 RESOLVE study (completion expected Q2 2027) and expects topline data from the CONVERGE analysis in Q3 2026. » Plus sur de.investing.com

The European Patent Office has granted Alpha Cognition a patent for a crystalline solid form of Benzgalantamin. The patent covers the specific form, pharmaceutical compositions, manufacturing processes and medical applications and can be validated in the member states of the European Patent Convention. Subject to applicable requirements, this could secure patent protection for the development and commercialization of ZUNVEYL until 2042. Alpha Cognition is also developing other Alzheimer therapies such as ALPHA-1062. » Plus sur de.investing.com